Pulmonary toxicity, such as interstitial lung disease, is a rare side effect associated with ALK inhibitors; most can be managed efficiently by lowering doses or interrupting treatment; crizotinib was responsible for adverse pulmonary interstitial lung disease and severe pneumonitis in a small percentage of patients (238) (239) (240); associated with ground-glass opacity predominant pattern interstitial lung disease (151)